dLife is reporting that Pfizer is dropping Exubera.
Since its market release in early 2006, Exubera has faced an uphill battle winning widespread physician and consumer adaption. Now, manufacturer Pfizer has decided to pull the product from its portfolio. From Pfizer's third quarter earnings release yesterday:
"[W]e made an important decision regarding Exubera, a product for which we initially had high expectations,” said Jeff Kindler, Chairman and Chief Executive Officer. “Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted.”
We will work with physicians to transition Exubera patients to other treatment options in the next three months. We remain committed to investing significant resources in the development of new and innovative medicines to manage diabetes, including monitoring inhalation technologies and other innovative delivery systems for insulin and other medicines.”